Biogen Plans To Update Its FY23 Financial Guidance In Conjunction With Its Q3 Earnings Release
Portfolio Pulse from Benzinga Newsdesk
Biogen is planning to update its FY23 financial guidance in conjunction with its Q3 earnings release. The company's acquisition of Reata is expected to be slightly dilutive to its Non-GAAP diluted Earnings Per Share (EPS) in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025.
July 28, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen's acquisition of Reata is expected to slightly dilute its EPS in 2023, be roughly neutral in 2024, and significantly accretive from 2025. This could impact investor sentiment and the company's stock price.
The acquisition of Reata by Biogen is expected to have a short-term dilutive effect on its EPS in 2023, which could negatively impact investor sentiment and the stock price. However, the impact is expected to be neutral in 2024 and significantly accretive from 2025, which could improve investor sentiment and positively impact the stock price in the long term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100